ES2167939T3 - Nuevas poliaminas, su preparacion y usos. - Google Patents
Nuevas poliaminas, su preparacion y usos.Info
- Publication number
- ES2167939T3 ES2167939T3 ES98946333T ES98946333T ES2167939T3 ES 2167939 T3 ES2167939 T3 ES 2167939T3 ES 98946333 T ES98946333 T ES 98946333T ES 98946333 T ES98946333 T ES 98946333T ES 2167939 T3 ES2167939 T3 ES 2167939T3
- Authority
- ES
- Spain
- Prior art keywords
- new
- polyamins
- preparation
- dna
- ribozymes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/14—Amines containing amino groups bound to at least two aminoalkyl groups, e.g. diethylenetriamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/42—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having etherified hydroxy groups and at least two amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C219/06—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/10—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Detergent Compositions (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La invención se refiere a nuevas lipopoliaminas (incluidas sus sales) caracterizadas por una fracción lipófila altamente flexible y simétrica que tiene una capacidad de amortiguación para un pH fisiológico. La invención se refiere también a su utilización para transportar, in vivo o in vitro, materias biológicamente activas por ejemplo, ADN, ARN, ribozimas, ADN anti-mensajero, péptidos y proteínas en el interior de célula eucarióticas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19735125 | 1997-08-13 | ||
DE19834683A DE19834683A1 (de) | 1997-08-13 | 1998-07-31 | Neue Lipopolyamine, deren Darstellung und Anwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2167939T3 true ES2167939T3 (es) | 2002-05-16 |
Family
ID=26039111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES98946333T Expired - Lifetime ES2167939T3 (es) | 1997-08-13 | 1998-08-13 | Nuevas poliaminas, su preparacion y usos. |
Country Status (8)
Country | Link |
---|---|
US (1) | US6281371B1 (es) |
EP (1) | EP1003711B1 (es) |
JP (1) | JP4504559B2 (es) |
AT (1) | ATE208369T1 (es) |
AU (1) | AU745958B2 (es) |
CA (1) | CA2299429C (es) |
ES (1) | ES2167939T3 (es) |
WO (1) | WO1999008997A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6583301B1 (en) | 1998-04-08 | 2003-06-24 | Celltech R & D Limited | Lipids |
US6852334B1 (en) * | 1999-04-20 | 2005-02-08 | The University Of British Columbia | Cationic peg-lipids and methods of use |
DE60035687T2 (de) * | 1999-04-26 | 2008-06-05 | Ucb Pharma, S.A. | Bipolare lipide und ihre verwendung zum transport bioaktiver substanzen |
WO2001043778A1 (en) * | 1999-12-17 | 2001-06-21 | Gene Therapy Systems, Inc. | Use of cationic lipids for intracellular protein delivery |
US7189705B2 (en) | 2000-04-20 | 2007-03-13 | The University Of British Columbia | Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers |
US7294511B2 (en) * | 2001-03-22 | 2007-11-13 | Chromos Molecular Systems, Inc. | Methods for delivering nucleic acid molecules into cells and assessment thereof |
US7001925B1 (en) | 2002-09-27 | 2006-02-21 | University Of Central Florida Research Foundation, Inc. | Compounds and method for enhancing the efficacy of anti-cancer drugs |
BRPI0411505A (pt) * | 2003-06-18 | 2006-07-25 | Yissum Res Dev Co | uso de um composto, método para modular a resposta imune de um indivìduo, composição farmacêutica, vacina, complexo, e, kit para a captura de uma molécula biologicamente ativa |
US7906122B2 (en) * | 2003-06-18 | 2011-03-15 | Yissum Research Development Company Of The Hebrew University Of Jersusalem | Sphingoid polyalkylamine conjugates for Hepatitis B virus vaccination |
US20110045001A1 (en) * | 2008-03-28 | 2011-02-24 | Biontex Laboratories Gmbh | Transfection results of non-viral gene delivery systems by influencing of the innate immune system |
WO2013016058A1 (en) * | 2011-07-22 | 2013-01-31 | Merck Sharp & Dohme Corp. | Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery |
EP3218012A1 (en) | 2014-11-10 | 2017-09-20 | ethris GmbH | Induction of osteogenesis by delivering bmp encoding rna |
JP2022522412A (ja) | 2019-02-14 | 2022-04-19 | エスリス ゲーエムベーハー | 繊毛病の治療 |
CA3196195A1 (en) | 2020-11-04 | 2022-05-12 | Carsten Rudolph | Use of ifn-lambda mrna for treating viral infections |
WO2024121160A1 (en) | 2022-12-05 | 2024-06-13 | Ethris Gmbh | Regulator(s) of energy homeostasis-encoding rna molecule(s) with increased translation efficiency |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1963189A1 (de) | 1969-12-17 | 1971-06-24 | Bayer Ag | Verfahren zur Herstellung von flammfesten,Urethangruppen aufweisenden Schaumstoffen |
US4339767A (en) | 1980-05-05 | 1982-07-13 | International Business Machines Corporation | High performance PNP and NPN transistor structure |
JP3250802B2 (ja) | 1989-03-21 | 2002-01-28 | バイカル・インコーポレイテッド | 脊椎動物における外因性ポリヌクレオチド配列の発現 |
FR2645866B1 (fr) * | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
US5538722A (en) | 1989-06-13 | 1996-07-23 | Stanford University | Isolation, growth, differentiation and genetic engineering of human muscle cells |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
IL103059A0 (en) | 1991-09-30 | 1993-02-21 | Boehringer Ingelheim Int | Conjugates for introducing nucleic acid into higher eucaryotic cells |
DE4139001A1 (de) * | 1991-11-27 | 1993-06-03 | Boehringer Mannheim Gmbh | Verfahren zur einschleusung von nukleinsaeuren in zellen |
US5972600A (en) | 1992-04-03 | 1999-10-26 | The Regents Of The University Of California | Separation of active complexes |
US5334761A (en) * | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
GB9218762D0 (en) | 1992-09-04 | 1992-10-21 | Exxon Chemical Patents Inc | Esters |
CN1119459A (zh) | 1993-03-19 | 1996-03-27 | 柏伦格-英格尔海姆国际股份公司 | 肿瘤疫苗的制备方法 |
US5777153A (en) | 1994-07-08 | 1998-07-07 | Gilead Sciences, Inc. | Cationic lipids |
US5650096A (en) * | 1994-12-09 | 1997-07-22 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
US5939401A (en) | 1994-12-09 | 1999-08-17 | Genzyme Corporation | Cationic amphiphile compositions for intracellular delivery of therapeutic molecules |
EP0833667A4 (en) | 1995-06-07 | 2001-11-21 | Univ California | STABILIZATION OF POLYNUCLEOTIDE COMPLEXES |
US5811406A (en) | 1995-06-07 | 1998-09-22 | Regents Of The University Of California | Dry powder formulations of polynucleotide complexes |
EP0830368A1 (en) | 1995-06-07 | 1998-03-25 | Genta Incorporated | Novel carbamate-based cationic lipids |
CA2223179A1 (en) | 1995-06-07 | 1996-12-19 | Bob Dale Brown | Phosphonic acid-based cationic lipids |
DE19521412A1 (de) | 1995-06-14 | 1996-12-19 | Boehringer Mannheim Gmbh | Neue kationische und polykationische Amphiphile, diese enthaltende Reagenzien und deren Verwendung |
CA2227373A1 (en) | 1995-07-21 | 1997-02-06 | Promega Biosciences, Inc. | Novel amide-based cationic lipids |
DE19607686A1 (de) | 1996-02-29 | 1997-09-04 | Chemicon Lab Gmbh | Neue metabolisierbare Lipopolyamine, deren Darstellung und Anwendung |
US5747509A (en) | 1996-06-03 | 1998-05-05 | Schering Aktiengesellschaft | Method for lowering plasma levels of lipoprotein(a) |
-
1998
- 1998-08-13 AT AT98946333T patent/ATE208369T1/de not_active IP Right Cessation
- 1998-08-13 CA CA2299429A patent/CA2299429C/en not_active Expired - Fee Related
- 1998-08-13 JP JP2000509683A patent/JP4504559B2/ja not_active Expired - Fee Related
- 1998-08-13 EP EP98946333A patent/EP1003711B1/de not_active Expired - Lifetime
- 1998-08-13 ES ES98946333T patent/ES2167939T3/es not_active Expired - Lifetime
- 1998-08-13 WO PCT/EP1998/005156 patent/WO1999008997A1/de active IP Right Grant
- 1998-08-13 US US09/463,172 patent/US6281371B1/en not_active Expired - Lifetime
- 1998-08-13 AU AU93421/98A patent/AU745958B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
EP1003711B1 (de) | 2001-11-07 |
JP4504559B2 (ja) | 2010-07-14 |
US6281371B1 (en) | 2001-08-28 |
CA2299429C (en) | 2010-04-20 |
CA2299429A1 (en) | 1999-02-25 |
ATE208369T1 (de) | 2001-11-15 |
JP2001515060A (ja) | 2001-09-18 |
WO1999008997A1 (de) | 1999-02-25 |
AU9342198A (en) | 1999-03-08 |
AU745958B2 (en) | 2002-04-11 |
EP1003711A1 (de) | 2000-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2167939T3 (es) | Nuevas poliaminas, su preparacion y usos. | |
ATE332918T1 (de) | Neoglycoproteine | |
DE60207198D1 (de) | Transplantate für die wiederherstellung von osteochondralen schäden | |
EP2292771A3 (en) | Sense mRNA therapy | |
BR9914643A (pt) | Vetores adeno-associados para expressão dofator viii por células alvo | |
TR199902529T2 (xx) | Etkinle�tirilmi� protein C form�lasyonlar�. | |
NO962791D0 (no) | Preparater inneholdende nukleinsyrer, deres fremstilling og anvendelse | |
ATE195721T1 (de) | Lipopolyamine als transfectionsmittel und ihre pharmazeutischen anwendungen | |
DK1093383T3 (da) | Lægemiddelafgivelsessystem omfattende et homeobox-peptid og et cytotoksisk eller antineoplastisk lægemiddel | |
BR9813658A (pt) | Cristais de peptìdeo-1 semelhantes a glucagÈnio | |
DK0749317T3 (da) | Terapeutiske anvendelser af dimerprodukter af baktericidt/permeabilitetsforøgende protein | |
EE200000012A (et) | Kimäärne glükosüleeritud lahustuva interleukiin-6 retseptori/interleukiin-6 valk ja selle bioloogiliselt aktiivsed analoogid, nende valmistamismeetod ja kasutamine, DNA järjestus, DNA vektor, transformeeritud imetajarakud ja farmatseutiline komposits | |
RU2011115418A (ru) | Усиление действия противораковых агентов | |
IT1318539B1 (it) | Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente | |
WO1997031934A3 (de) | Neue metabolisierbare lipopolyamine, deren darstellung und anwendung | |
PT883602E (pt) | Compostos lipidicos e sua utilizacao por exemplo em lipossomas | |
DE60028022D1 (de) | Herstellung von biologisch aktiven molekülen | |
EP1426058A3 (de) | Flüssige Interferon-Beta Formulierungen | |
FR2763943B1 (fr) | Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules | |
IT1299583B1 (it) | Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica | |
WO2000037487A8 (de) | INHIBITOREN DES INTEGRINS αvβ¿6? | |
EA200000270A1 (ru) | КОМПОЗИЦИИ ДЛЯ ГЕНОТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ ГЕНОВ, КОДИРУЮЩИХ СЕКРЕТИРУЕМЫЕ БЕЛКИ, ТАКИЕ КАК β-ИНТЕРФЕРОН, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
UY27373A1 (es) | Formulaciones de interferón beta-humano | |
WO2000066173A3 (en) | Targeting of infectious agents bearing host cell proteins | |
DE69910809D1 (de) | Verwendung von OmpA Enterobakterproteinen um zielgerichtet Antigen-Präsentierende Zellen anzusteuern |